At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Trebananib +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Trebananib for Adult Angiosarcoma and 3 related conditions. Completed, enrolled 16 participants across 70 sites.
Detailed Summary
This phase II trial studies how well trebananib works in treating patients with advanced angiosarcoma that cannot be removed by surgery. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartJul 2012
Primary CompletionSep 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedJun 20, 2012
Enrollment StartJul 1, 2012
Primary CompletionSep 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 14.0 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Trebananibbiological
Given IV